BC
AMRX icon

Bridgefront Capital’s Amneal Pharmaceuticals AMRX Stock Holding History

Bridgefront Capital’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-13,275
Closed -$89K – 593
2021
Q1 		$89K Buy
+13,275
New +$73.6K 0.03% 626

Other funds holding AMRX

FI
Fosun International Hong Kong, China $446M AUM 13.33% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

Bridgefront Capital's AMRX Position: Q2 2021 in Review

Bridgefront Capital sold out of Amneal Pharmaceuticals (AMRX) in Q2 2021, closing a stake of 13,275 shares — an estimated $89K sold.

Bridgefront Capital first reported a position in AMRX in Q1 2021 and held it in 1 quarter. The position peaked at $89K in Q1 2021. 160 funds tracked by Wall St. Rank hold AMRX as of Q2 2021.

  • Bridgefront Capital reported no remaining Amneal Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • Bridgefront Capital sold 13,275 Amneal Pharmaceuticals shares in Q2 2021, an estimated $89K.
  • Bridgefront Capital first reported a position in Amneal Pharmaceuticals in Q1 2021 and held it in 1 quarter.
  • Bridgefront Capital's Amneal Pharmaceuticals position peaked at $89K in Q1 2021.
  • 160 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q2 2021.

Based on Bridgefront Capital's 13F filing for Q2 2021, filed 12 Aug 2021.